Page last updated: 2024-09-03

lestaurtinib and Neoplasms

lestaurtinib has been researched along with Neoplasms in 3 studies

Research

Studies (3)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (33.33)	29.6817
2010's	2 (66.67)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asami, Y; Crump, A; Ōmura, S	1
Ashworth, A; Burn, J; Clewes, O; Elliott, R; Langtry, J; Lord, CJ; Mackay, A; Rajan, N; Reis-Filho, JS; Sieber-Blum, M	1
Bhargava, P; Boylan, S; Deeken, J; Dordal, M; Hawkins, MJ; Kindler, H; Luhtala, T; Marshall, JL; Ratain, MJ; Rizvi, N; Robertson, P; Vogelzang, NJ	1

Reviews

1 review(s) available for lestaurtinib and Neoplasms

Article	Year
Staurosporine: new lease of life for parent compound of today's novel and highly successful anti-cancer drugs. The Journal of antibiotics, 2018, Volume: 71, Issue:8 Topics: Anti-Bacterial Agents; Antineoplastic Agents; Bacteria; Bacterial Infections; Carbazoles; Drug Discovery; Furans; Humans; Imatinib Mesylate; Neoplasms; Protein Kinase Inhibitors; Staurosporine	2018

Trials

1 trial(s) available for lestaurtinib and Neoplasms

Article	Year
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor. Investigational new drugs, 2005, Volume: 23, Issue:1 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Carbazoles; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Furans; Humans; Indoles; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Receptor, trkA	2005

Other Studies

1 other study(ies) available for lestaurtinib and Neoplasms

Article	Year
Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours. Oncogene, 2011, Oct-13, Volume: 30, Issue:41 Topics: Adenoma, Sweat Gland; Carbazoles; Carcinoma, Adenoid Cystic; Cluster Analysis; Comparative Genomic Hybridization; Deubiquitinating Enzyme CYLD; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Mutation; Neoplasms; Neoplasms, Basal Cell; Oligonucleotide Array Sequence Analysis; Primary Cell Culture; Protein Kinases; Receptor, trkB; Receptor, trkC; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sweat Gland Neoplasms; Tissue Array Analysis; Tumor Cells, Cultured; Tumor Suppressor Proteins	2011

Article

Year

Dysregulated TRK signalling is a therapeutic target in CYLD defective tumours.

Oncogene, 2011, Oct-13, Volume: 30, Issue:41

Topics: Adenoma, Sweat Gland; Carbazoles; Carcinoma, Adenoid Cystic; Cluster Analysis; Comparative Genomic Hybridization; Deubiquitinating Enzyme CYLD; Furans; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Immunoblotting; Immunohistochemistry; Mutation; Neoplasms; Neoplasms, Basal Cell; Oligonucleotide Array Sequence Analysis; Primary Cell Culture; Protein Kinases; Receptor, trkB; Receptor, trkC; Reverse Transcriptase Polymerase Chain Reaction; RNA Interference; Signal Transduction; Sweat Gland Neoplasms; Tissue Array Analysis; Tumor Cells, Cultured; Tumor Suppressor Proteins

2011